Iron Path Capital Closes Fund I, Exceeds Target at $273 Million

Charlottesville, VA and Nashville, TN – July 2, 2024 | Iron Path Capital (“Iron Path” or “IPC”), an operationally focused private equity firm investing in the specialty industrials and healthcare sectors, today announced the final closing of Iron Path Capital Fund I (“Fund I”), exceeding the $250 million target  with total commitments of $273 million. The Fund I limited partners consist of a diverse group of global investors including leading endowments, fund of funds, institutional investors and family offices.

The Chemours Company Agrees to Sell Glycolic Acid Business to Iron Path Capital-backed PureTech Scientific Inc. for $137 Million

WILMINGTON, Del., NASHVILLE, Tn, June 1, 2023 — The Chemours Company (Chemours) (NYSE: CC), a global chemistry company with leading market positions in Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials has entered into a definitive agreement to sell its Glycolic Acid business (“Glycolic Acid”) for $137 million in cash to PureTech Scientific Inc., a company founded and backed by Iron Path Capital, a private equity firm focused on lower-middle market investments across the specialty industrial and healthcare sectors.